Clinical trials
CAR clinical trials
Below are recruiting car clinical trials, each written for real people, not researchers. We’re tracking 733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07558850Recruiting
CAR-T Cell Therapy for Treatment-Resistant Autoimmune Diseases
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
Nanjing, JiangsuAges 18–70 - NCT07551349RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Kidney Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to target kidney cancer that has spread or cannot be removed with surgery. The cells are engineered in the lab to recognize and attack cancer cells, and may help patients whose cancer has grown despite previous treatments.
Shenzhen, GuangdongAges 18 years+ - NCT07543055RecruitingPhase 1
CAR T-Cell Therapy for Advanced Prostate Cancer
This trial tests BPX-601, a new type of cell therapy that uses your own immune cells to fight prostate cancer that has spread and stopped responding to hormone treatments. The study aims to see if this approach can help men whose cancer has returned despite multiple prior treatments.
Atlanta, GeorgiaAges 18 years+ - NCT06071871RecruitingPhase 2
A trial of 3 drugs before or after CAR-T for lymphoma
This trial tests a combination of three drugs (polatuzumab vedotin, obinutuzumab, and glofitamab) for people with a type of large B-cell lymphoma. It is given either as a bridge treatment before CAR-T cell therapy or to those who did not fully respond to CAR-T.
LondonAges 18 years+ - NCT05807789Recruiting
Genetic testing during CAR-T treatment for adults
This study looks at a patient’s genetic (molecular) information while they receive CAR-T cell therapy. The goal is to better understand how different biological factors may affect CAR-T treatment.
Bologna, ItalyAges 18–70 - NCT07538635RecruitingPhase 2
CAR-T cells plus stem cell transplant for aggressive lymphoma
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
Hangzhou, ZhengjiangAges 18 years+ - NCT07541391RecruitingPhase 1
CAR T-cell therapy for relapsed kappa myeloma
This trial tests a new treatment called CAR T-cells (your own immune cells engineered in the lab) designed to fight kappa-restricted multiple myeloma that has come back or stopped responding to standard drugs. The goal is to see if this treatment can help patients whose cancer has progressed despite previous therapies.
Melbourne, VictoriaAges 18 years+ - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT06734871RecruitingPhase 1
Study of CT1190B for relapsed or refractory B-cell lymphoma
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07516288RecruitingPhase 1
Second CAR-DC Cell Infusion for Advanced Heart Failure
This trial tests a second dose of specialized immune cells (called CAR-DC) in patients with severe dilated cardiomyopathy (a weakened heart muscle) who received one dose before but saw their heart function decline back to baseline. The goal is to see if a second dose is safe and can improve heart function when the first treatment's benefits wore off.
Hangzhou, Zhejiang / 浙江Ages 18–75 - NCT07517536Enrolling by invitation
CHT105 treatment for hard-to-treat lupus kidney disease
This study tests a new medicine called CHT105 for lupus patients whose kidney disease hasn't improved with standard treatments. The medicine targets specific immune cells that may be driving the kidney damage.
Nanjing, JiangsuAges 18–65 - NCT07509450Recruiting
Fecal transplant study for CAR-T and stem cell transplant patients
This pilot study tests whether giving a fecal microbiota transplant before standard CAR-T therapy (for B-cell lymphoma) or reduced-intensity stem cell transplant (for AML or high-risk MDS) can improve treatment outcomes. It aims to see if restoring gut bacteria helps reduce complications.
Toronto, OntarioAges 18 years+ - NCT07502287RecruitingPhase 1/Phase 2
Dual-target CAR-NK cell therapy for children with neuroblastoma
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
Shenzhen, GuangdongAges 1–21 - NCT07507201RecruitingEarly Phase 1
Car-T cells for autoimmune diseases like lupus
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
Hangzhou, ZhejiangAges 3 years+ - NCT07505199RecruitingPhase 1
Immune cell therapy for advanced heart failure from blocked arteries
This early-phase study tests a new type of immune cell therapy (CAR-DC) for people with advanced heart failure due to blocked arteries. It aims to see if the treatment is safe and may help improve heart function.
Hangzhou, Zhejiang / 浙江Ages 18–75 - NCT07490041RecruitingEarly Phase 1
CAR-NK cell therapy for refractory childhood rheumatic diseases
This trial is testing a new type of cell therapy (CAR-NK cells) that targets two markers on immune cells (CD19 and BCMA) to treat severe forms of childhood rheumatic diseases. It aims to see if this treatment is safe and can help when other medicines have failed.
Hangzhou, ZhejiangAges 5 years+ - NCT07492628RecruitingPhase 1
Dual-target cell therapy for advanced bladder cancer
This trial tests a new treatment that uses your own immune cells, called CAR-NK cells, modified to attack two proteins (Nectin-4 and HER2) often found on bladder cancer cells. It is for people whose cancer has spread or cannot be removed by surgery and has not responded to standard treatments like chemotherapy or immunotherapy.
Shenzhen, GuangdongAges 18–75 - NCT07488923RecruitingPhase 1
ML261 CAR T therapy for advanced small cell lung cancer and related neuroendocrine cancers
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
St Louis, MissouriAges 18 years+ - NCT07487597RecruitingEarly Phase 1
Engineered T cell therapy for ALPP-positive advanced solid tumors
This trial tests a new type of immune cell therapy designed to target and attack cancer cells that have a specific marker called ALPP. It is for people with advanced solid tumors who have not responded to or cannot have standard treatments.
Nanjing, JiangsuAges 18–70 - NCT07474051Enrolling by invitation
Long-term follow-up for CAR-T cell therapy patients
This study tracks people who received a specific CAR-T cell therapy made by AvenCell. The goal is to monitor their health over time to better understand long-term effects.
BerlinAges Any age - NCT07479927Recruiting
Online brain training and mindfulness for kids after leukemia treatment
This study tests if a computer-based training program focusing on thinking skills and mindfulness can help children and teens who have had leukemia treatment. It may help improve memory, attention, and emotional well-being.
Madrid, MadridAges 8–18 - NCT07472972Recruiting
Personalized risk tracking for CD19 CAR T therapy
This study follows patients with relapsed or hard-to-treat B-cell lymphoma who are receiving CD19-directed CAR T cell therapy. Researchers collect blood and tissue samples to better understand each patient's unique risk profile, aiming to improve how the treatment is monitored and managed.
Zurich, Canton of ZurichAges Any age - NCT06783816Recruiting
New immune cell therapy for blood cancers
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
Taiyuan, ShanxiAges Any age - NCT07470073RecruitingEarly Phase 1
Universal CAR-T cell therapy for B-cell leukemia (ages 12-75)
This trial tests a new type of CAR-T cell therapy (called universal CAR-T) that targets CD19 and CD20 markers on cancer cells. It is for people aged 12 to 75 with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back after treatment.
Wuhan, HubeiAges 12–75
Hear when a new CAR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car?
- Yes. Clin2 currently lists 733 recruiting car studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.